Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 397 trials

Prostate Cancer: Saruparib and Darolutamide Study

We are examining the effects of Saruparib and Darolutamide, both alone and together, in men with newly diagnosed prostate cancer. This research aims to understand how these treatments may impact patients before surgery.

Newly Diagnosed Prostate Cancer6-12 monthsSafety phase (I)OncologyUrology

Aspirin for Preeclampsia Prevention in Twin Pregnancies

We are studying whether low-dose aspirin can help prevent preeclampsia in women expecting twins. This research aims to improve outcomes for mothers and their babies.

Preeclampsia6-12 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesGynecology and ObstetricsInternal Medicine

Mild Male Factor Infertility: PKB171 Gel Study

We are testing a new intravaginal gel to see if it helps couples with mild male factor infertility achieve pregnancy. The study compares the gel's effects to a placebo over three treatment cycles.

Male Infertility6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteGynecology and ObstetricsUrology

Hip Replacement Pain Management: Néfopam Study

We are studying the effects of néfopam on pain relief after hip replacement surgery. This trial compares its use against a placebo to see if it helps reduce the need for morphine and improves recovery.

Hip Replacement Surgery6-12 monthsConfirmation phase (III)Standard MedicinesInternal MedicineOrthopedics and Traumatology

Nipocalimab for Generalized Myasthenia Gravis

We are studying whether nipocalimab IV infusions can help adults with generalized myasthenia gravis perform daily activities better than a placebo. This research aims to assess its effectiveness and safety.

Myasthenia Gravis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Eosinophilic Granulomatosis With Polyangiitis: NS-229 Study

We are testing a new treatment, NS-229, to see if it helps patients with Eosinophilic Granulomatosis With Polyangiitis achieve remission better than a placebo. The study will also look at any side effects and the time until symptoms worsen.

Eosinophilic Granulomatosis with Polyangiitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Advanced Solid Tumors: [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 Study

We are studying the safety and effectiveness of two new treatments for patients with advanced solid tumors that cannot be removed by surgery. This trial also looks at how well these treatments can help in imaging the tumors.

Colorectal CancerDuctal Adenocarcinoma of PancreasClear Cell Renal Cell Carcinoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Glofitamab for Pediatric B-Cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of glofitamab alone and with other treatments for children and young adults with relapsed or refractory B-cell non-Hodgkin lymphoma. This research aims to find better options for managing this challenging cancer.

B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Lower Respiratory Infections: Acyclovir Therapy

We are studying whether acyclovir can help ventilated patients with lower respiratory infections and herpes simplex virus. The trial aims to see if it improves survival and reduces hospital stays.

Pneumonia with Herpes Simplex Virus Infection6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Pulmonary Arterial Hypertension: Triple Therapy Study

We are investigating whether a new combination of treatments, including an injectable medication, improves health outcomes for patients with pulmonary arterial hypertension. This study compares it to a standard oral treatment to see which is more effective.

Pulmonary Arterial Hypertension6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

aHUS: Switching to Iptacopan Treatment

We are studying whether switching from anti-C5 antibody therapy to iptacopan can help people with aHUS avoid complications. The trial will also assess the safety and effects on blood and kidney health.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyNephrology

Cell Therapy for Acute Kidney Injury After Heart Surgery

We are studying whether modified autologous leukocyte cells can help patients recover kidney function after developing acute kidney injury following cardiac surgery. The trial will also assess the safety of this new treatment.

Acute Kidney Injury6-12 monthsEfficacy phase (II)Investigational MedicinesCardiologyNephrology

Triple-Negative Breast Cancer: Pembrolizumab and Chemotherapy Study

We are investigating whether adding pembrolizumab to chemotherapy improves outcomes for patients with early-stage triple-negative breast cancer based on their tumor-infiltrating lymphocyte levels. This study also looks at the safety and quality of life for participants.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)Standard MedicinesOncology

Cholestatic Pruritus: Volixibat Study

We are testing a new drug, volixibat, for patients with itching caused by primary biliary cholangitis. The study aims to see if it can reduce itching and improve quality of life compared to a placebo.

Primary Biliary Cholangitis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInternal Medicine

Vitamin D Deficiency: Cholecalciferol Study for Postmenopausal Women

We are investigating the right dose of Cholecalciferol to help postmenopausal women with vitamin D deficiency. The study also looks at how satisfied participants are with this vitamin D supplement.

Postmenopausal Women6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

HER2-Expressing Tumors: Trastuzumab Deruxtecan Study

We are studying the safety and effectiveness of Trastuzumab Deruxtecan in patients with advanced HER2-expressing tumors. This research aims to provide insights into new treatment possibilities for these patients.

HER2 Expressing Tumors6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Cystic Fibrosis: VX-522 Treatment Study

We are testing a new medication, VX-522, for adults with cystic fibrosis who do not respond to current treatments. The study will help us understand its safety and effectiveness compared to existing therapies.

Cystic Fibrosis6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPulmonology

Pediatric Cancer: Crizotinib Treatment Study

We are testing the safety and effectiveness of crizotinib, alone and with temsirolimus, for children with ALK, ROS1, or MET positive cancers. This study aims to find the best dose and understand how well these treatments work.

NeuroblastomaAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Chronic Kidney Disease in Children: Finerenone Study

We are studying how well finerenone works and its safety for children with chronic kidney disease and proteinuria. This trial will help us understand its effects when used with standard treatments.

ProteinuriaChronic Kidney Disease6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Non-Transfusion-Dependent Thalassemia: Luspatercept Treatment

We are studying whether luspatercept can improve brain oxygen levels and blood flow in patients with non-transfusion-dependent thalassemia. The trial also looks at its effects on cognitive function and heart health.

Non-transfusion Dependent Beta-Thalassemia6-12 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHematologyNeurology